Literature DB >> 3785422

A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity.

A H Underwood, J C Emmett, D Ellis, S B Flynn, P D Leeson, G M Benson, R Novelli, N J Pearce, V P Shah.   

Abstract

A number of agents that mimic the ability of the thyroid hormone, T3, to decrease plasma cholesterol levels are described; one is as effective as T3 at reducing cholesterol levels and stimulating liver function, but has very little effect on cardiac function and is thus less likely to be toxic. The agent may be useful in the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3785422     DOI: 10.1038/324425a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  18 in total

Review 1.  Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport.

Authors:  Matteo Pedrelli; Camilla Pramfalk; Paolo Parini
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

2.  The disposition of SK&F L-94901, a selective thyromimetic in rat, dog and cynomolgus monkey.

Authors:  M A Pue; J A Ransley; D J Writer; A J Dean; E R Franklin; I G Beattie; D A Ross
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

3.  Thyroid hormone: a resurgent treatment for an emergent concern.

Authors:  Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-09-27       Impact factor: 5.464

Review 4.  The molecular basis of thyroid hormone action.

Authors:  L J DeGroot; A Nakai; A Sakurai; E Macchia
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

5.  Thyromimetic mode of action of peroxisome proliferators: activation of 'malic' enzyme gene transcription.

Authors:  R Hertz; V Nikodem; A Ben-Ishai; I Berman; J Bar-Tana
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

6.  Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.

Authors:  Mark D Erion; Edward E Cable; Bruce R Ito; Hongjian Jiang; James M Fujitaki; Patricia D Finn; Bao-Hong Zhang; Jinzhao Hou; Serge H Boyer; Paul D van Poelje; David L Linemeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

7.  Fatty acid turnover rates in the adipose tissues of the growing chicken (Gallus domesticus).

Authors:  T A Foglia; A L Cartwright; R J Gyurik; J G Philips
Journal:  Lipids       Date:  1994-07       Impact factor: 1.880

Review 8.  The resurgence of thyromimetics as lipid-modifying agents.

Authors:  Ivan Tancevski; Philipp Eller; Josef R Patsch; Andreas Ritsch
Journal:  Curr Opin Investig Drugs       Date:  2009-09

9.  Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.

Authors:  Gary J Grover; Karin Mellström; Liu Ye; Johan Malm; Yi-Lin Li; Lars-Göran Bladh; Paul G Sleph; Mark A Smith; Rocco George; Björn Vennström; Kasim Mookhtiar; Ryan Horvath; Jessica Speelman; Donald Egan; John D Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

Review 10.  The biochemistry of lipoproteins.

Authors:  A M Salter; D N Brindley
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.